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Developmental programming in human 
umbilical cord vein endothelial cells 
following fetal growth restriction
Fieke Terstappen1,2* , Jorg J. A. Calis3,4, Nina D. Paauw1, Jaap A. Joles5, Bas B. van Rijn6, Michal Mokry3, 
Torsten Plösch7 and A. Titia Lely1
Abstract 
Background: Fetal growth restriction (FGR) is associated with an increased susceptibility for various noncommuni-
cable diseases in adulthood, including cardiovascular and renal disease. During FGR, reduced uteroplacental blood 
flow, oxygen and nutrient supply to the fetus are hypothesized to detrimentally influence cardiovascular and renal 
programming. This study examined whether developmental programming profiles, especially related to the cardio-
vascular and renal system, differ in human umbilical vein endothelial cells (HUVECs) collected from pregnancies com-
plicated by placental insufficiency-induced FGR compared to normal growth pregnancies. Our approach, involving 
transcriptomic profiling by RNA-sequencing and gene set enrichment analysis focused on cardiovascular and renal 
gene sets and targeted DNA methylation assays, contributes to the identification of targets underlying long-term 
cardiovascular and renal diseases.
Results: Gene set enrichment analysis showed several downregulated gene sets, most of them involved in immune 
or inflammatory pathways or cell cycle pathways. seven of the 22 significantly upregulated gene sets related to 
kidney development and four gene sets involved with cardiovascular health and function were downregulated in FGR 
(n = 11) versus control (n = 8). Transcriptomic profiling by RNA-sequencing revealed downregulated expression of 
LGALS1, FPR3 and NRM and upregulation of lincRNA RP5-855F14.1 in FGR compared to controls. DNA methylation was 
similar for LGALS1 between study groups, but relative hypomethylation of FPR3 and hypermethylation of NRM were 
present in FGR, especially in male offspring. Absolute differences in methylation were, however, small.
Conclusion: This study showed upregulation of gene sets related to renal development in HUVECs collected from 
pregnancies complicated by FGR compared to control donors. The differentially expressed gene sets related to cardio-
vascular function and health might be in line with the downregulated expression of NRM and upregulated expression 
of lincRNA RP5-855F14.1 in FGR samples; NRM is involved in cardiac remodeling, and lincRNAs are correlated with car-
diovascular diseases. Future studies should elucidate whether the downregulated LGALS1 and FPR3 expressions in FGR 
are angiogenesis-modulating regulators leading to placental insufficiency-induced FGR or whether the expression 
of these genes can be used as a biomarker for increased cardiovascular risk. Altered DNA methylation might partly 
underlie FPR3 and NRM differential gene expression differences in a sex-dependent manner.
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original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or 
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to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory 
regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this 
licence, visit http://creat iveco mmons .org/licen ses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creat iveco 
mmons .org/publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
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Introduction
Fetal growth restriction (FGR) describes the condition in 
which the fetus fails to reach its genetically determined 
growth potential. FGR most commonly results from pla-
cental insufficiency, in which a reduced uteroplacental 
blood flow, oxygen, and nutrients toward the fetus lead 
to aberrant fetal growth. Compensatory physiological 
mechanisms are set in motion, such as fetal hemody-
namic redistribution over organs and epigenetic altera-
tions; while these fetal adaptations might improve fetal 
survival, they are considered to be unfavorable in the 
long run.
FGR is linked to an increased susceptibility for various 
noncommunicable diseases in adulthood, including car-
diovascular and renal disease [1–4]. The Developmen-
tal Origins of Health and Disease (DOHaD) hypothesis 
states that this predisposition originates in the womb, 
when the adverse in utero environment influences epi-
genetic developmental programming [5–7]. Preclinical 
research strongly supports sex-specific programming of 
cardiovascular and renal disease in FGR offspring [8]. 
However, evidence for this concept has been less evi-
dent in humans [9, 10]. Epigenetic differences have been 
observed in placental tissue and cord blood collected 
from pregnancies in which babies were born with a low 
birth weight (as a surrogate marker for FGR). Most stud-
ies investigated DNA methylation and identified epige-
netic DNA methylation markers related to impaired fetal 
growth [11, 12].
While placental tissue can be used to examine gene 
expression or epigenetic changes in pregnancies com-
plicated by FGR, this tissue consists of a combination of 
maternal and fetal cells. Therefore, human umbilical vein 
endothelial cells (HUVECs) can be used to examine the 
fetal profile of disrupted growth without contamination 
by maternal cells. Therefore, HUVECs are especially rel-
evant cell type in context of the fetal origin of cardiorenal 
disease. The few studies performed in cultured HUVECs 
report different proteome profiles in cultured HUVECs 
from FGR compared to control donors and differential 
protein expression and DNA methylation in the eNOS 
pathway [13–15]. However, transcriptomic profiling by 
RNA-sequencing of primary HUVECs derived from FGR 
compared to control donors, without culturing bias, has 
to our knowledge not yet been reported. In addition, the 
expression of gene sets related to cardiovascular or renal 
development and function has not been analyzed in this 
condition.
This study aims to examine whether developmental 
programming profiles, especially related to the cardio-
vascular and renal systems, differ in HUVECs collected 
from pregnancies complicated by placental insufficiency-
induced FGR compared to normal growth pregnancies. 
We explored this by whole-genome RNA-sequencing to 
map differential expression per gene and gene set enrich-
ment analysis (GSEA) focussed on cardiovascular and 
renal development, function and health. Additionally, we 
performed targeted DNA methylation assays in candidate 
genes to gain insight in whether DNA methylation plays a 
regulatory role in the different expression. This approach 
contributes to the identification of early targets that can 
be aimed at to predict or prevent long-term diseases.
Methods
Study population
Pregnant women with placental insufficiency-induced 
FGR and pregnant woman with normal grown fetuses 
were included in this prospective observational study 
in the Wilhelmina Children’s Hospital from July 2016 to 
December 2017. Inclusion criteria for placental insuffi-
ciency-induced FGR cases were described [16], but in 
short were diagnosed by prenatal ultrasound when (1) 
estimated fetal weight or abdominal circumference was 
below  10th percentile for gestational age, in combination 
with (2) signs of placental insufficiency defined as abnor-
mal blood flow patterns in umbilical artery, fetal middle 
cerebral artery, cerebral–placental ratio, or deflecting 
fetal growth rate in at least three consecutive measure-
ments. The control group consisted of pregnancies with 
normal fetal growth defined as estimated fetal weight or 
abdominal circumference between p10–90. Percentiles of 
prenatal biometry were determined using the perinatol-
ogy biometry calculator (http://www.perin atolo gy.com/
calcu lator s/biome try.htm). Exclusion criteria were con-
genital disorders, multiple pregnancies and stillbirth. 
The Medical Ethical Committee of the University Medi-
cal Center Utrecht approved the study on July 19, 2016, 
protocol number 16-302. Written informed consent was 
obtained from parents prior to delivery.
Clinical data
Clinical data were derived from electronic patient 
records (HiX, Chipsoft B.V., the Netherlands). Maternal 
comorbidities and cardiovascular familiarities included 
BMI, and smoking, preexisting hypertension, cardiovas-
cular or renal diseases (including congenital disorders), 
Keywords: Developmental programming, DNA methylation, Epigenetics, Fetal growth restriction, FPR3, Gene set 
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preeclampsia, diabetes, autoimmune disorders. Use 
of maternal medication was registered. Percentiles for 
weight and head circumference at birth were determined 
with Intergrowth-21st [17]. Neonatal complications 
included infant respiratory distress syndrome, intraven-
tricular hemorrhage, sepsis and necrotizing enterocolitis.
HUVECs isolation
Directly after placental delivery, the umbilical cord was 
stored in phosphate buffered saline (PBS) solution (pH 
7.2;) at 4  °C. HUVECs isolation occurred preferably 
within 12 h, but always within 24 h after placental deliv-
ery as described [18]. Umbilical cords from n = 8 con-
trol and n = 12 FGR cases were collected. Cannulation 
of the umbilical vein at one end allowed access to wash 
with sterile PBS (pH 7.4; Gibco by Life Technologies, 
Grand Island, NY). Hereafter, the umbilical cord was 
clamped at both ends in order to incubate with accutase 
(0.02 µg/ml DNase; Innovative cell technologies Inc, San 
Diego, CA) for 5  min in sterile PBS at 37  °C to detach 
the endothelial cells from the umbilical vein. Detached 
HUVECs in accutase were flushed out of the umbilical 
vein with endothelial cell growth medium-2 (97% EGM-
2; basal medium and SingleQuots supplement [1.9% FBS, 
0.04% hydrocortisone, 0.4% hFGF-B2, 0.1% VEGF, 0.1% 
R3-IGF-1, 0.1% ascorbic acid, 0.1% hEGF, 0.1% GA-1000, 
0.1% heparin], Lonza Bioscience, Walkersville, MD) and 
centrifuged in two separate tubes for 5 min 330 g at room 
temperature. One pellet was resuspended in 600 μl RA1 
lysis buffer (Macherey–Nagel, Düren, Germany) and 6 μl 
1 M DTT and stored at − 80 °C until RNA isolation. The 
second pellet was resuspended in 0.5 ml EMG-2 medium 
and 0.5  ml freezing medium with 20% DMSO and was 
frozen in a freezing container overnight and stored in liq-
uid nitrogen the next day until DNA isolation.
RNA isolation and RNA‑sequencing
RNA was isolated using NucleoSpin RNA® (Macherey–
Nagel), with RNA elution in 40  μl nuclease-free water. 
The concentration of RNA was quantified using Qubit 
RNA HS assay and Qubit fluorometer (Thermo Fisher). 
RNA-sequencing was performed as described [19]. In 
short, libraries were generated using NEXTFlexTM 
Rapid RNA-seq Kit (Bio Scientific) and sequenced by the 
Nextseq500 platform (Illumina) to produce 75 bp single-
end reads through the Utrecht DNA sequencing facil-
ity. Reads were aligned to the human reference genome 
GRCh37 using STAR.
Gene set analysis
Gene set enrichment testing was performed on the 
hallmark (H), canonical pathway (C2-CP) and select 
GO term (C5) gene set collections from the Molecular 
Signatures Database (version 7.1) [20, 21]. Only gene sets 
with relation to renal or cardiovascular development, 
function and health were selected from the GO term 
gene sets (Additional file  1: Table  S1). Gene sets with 
less than five genes in the set of selected genes (based on 
expression, see below) were excluded from the analysis, 
eventually resulting in 2167 included gene sets.
DNA isolation and methylation
Genomic DNA from HUVEC was isolated with the all-
prep DNA/RNA mini kit (Qiagen, Venlo, the Nether-
lands), following the manufacturer’s protocol. DNA 
quantity was measured with a Nanodrop 2000c (Thermo 
Scientific, Pittsburgh, PA). DNA was stored at −  80  °C 
until further analysis.
Targeted DNA methylation assaying was performed 
blindly in the significant differential expressed genes. 
Bisulfite conversion of 200 ng DNA was performed with 
the EZ DNA Methylation-Gold kit (Zymo Research, Lei-
den, the Netherlands) according to the manufacturers’ 
protocol. Pyrosequencing primers were designed for 
the top three differentially expressed genes targeting the 
promoter regions (Additional file  2: Table  S2) using the 
PyroMark Assay design 2.0 software (Qiagen). HotStar-
Taq master mix (Qiagen) was used for amplification of 
20 ng of bisulfite-treated DNA using the following steps: 
DNA polymerase activation (95  °C, 15  min), three-step 
cycle of denaturation (94 °C, 30 s), annealing (FPR3 54 °C, 
LGALS1 56  °C, and NRM 56  °C; 30  s), and extensions 
(72  °C, 30  s) repeated for 45 cycles in a row. The final 
extension was carried out at 72 °C for 7 min.
The polymerase chain reaction product was analyzed 
for the extent of methylation per selected CpG positions 
on a PyroMark Q24 (Qiagen). Data were analyzed using 
the PyroMark Q24 Analysis Software 2.0 (Qiagen).
Statistical analysis
Clinical data
Statistical analysis was performed in IBM SPSS Statis-
tics 25 for Windows, version 25 (IBM Corp, Armonk, 
NY). Parametric data are presented as mean ± SD and 
tested with independent t test, nonparametric data are 
presented as median (minimum–maximum) and tested 
with Mann–Whitney, and nominal data are presented as 
n (%) and tested with Fisher exact. A two-sided p value 
of ≤ 0.05 was considered significant.
Differential expression of genes
Read counts per gene, per sample, were analyzed for 
global expression differences using R (version 3.5.3). 
Genes were selected with an expression of one count per 
million reads (CPM) in at least eight samples (n = 13,760 
genes selected). Read counts were TMM-normalized 
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using the calcNormFactors function from the edgeR 
package (version 3.24.3) [22]. TMM-normalized counts 
were used to assess global transcriptional profile dif-
ferences of all samples by principal component analysis 
(PCA). Ten principal components (PC) were analyzed in 
the PCA analysis; values from each PC were checked for 
correlation to sample characteristics by the Mann–Whit-
ney U test implemented in the SciPy package (version 
0.19.0) in python (version 2.7.10). Outliers in RNA-seq 
data were identified and removed when (1) the number of 
reads was less than 1.000.000; (2) the number of nonzero 
genes was less than 10.000 or (3) a combination of num-
ber of nonzero genes was between 10.000 and 12.000 and 
a visible outlier on one of the PCA components. One 
outlier was identified; thus, n = 11 FGR and n = 8 control 
samples were selected for differential expression analysis.
Differential gene expression analysis was performed 
with the edgeR package (version 3.24.3) in R (version 
3.5.3). Gene expression was modeled using the glmQLFit 
function in EdgeR [22], to a model that included patient 
group variables, as well as factors to capture Mode of 
Delivery (caesarean section vs. spontaneous delivery), 
Sex (male vs. female), and Gestational stage (preterm vs. 
term)-related gene expression variation. Differential gene 
expression was determined between study population 
groups (FGR vs. control). Differential expression statis-
tics were obtained using the glmQLFTest functionality 
in edgeR; false discovery rates (FDRs) were determined 
using the Benjamini–Hochberg method to adjust for 
multiple testing and considered significant when below 
0.1 (in combination with p value below 0.05) [23].
Gene set analysis
Gene set enrichment testing was performed with CAM-
ERA, using the same linear model and contrasts as in 
the differential gene expression analysis (see above), and 
FDRs were also determined using the Benjamini–Hoch-
berg method [23]. When a module showed ≥ 50% over-
lap with a higher ranking gene set, we selected the more 
significant gene set. Heatmaps for the gene sets related 
to the cardiovascular and renal development or function 
were created.
DNA methylation
The level of DNA methylation is given as a percentage, 
and since sex-specific differences have been reported in 
HUVECs and DNA methylation assays in other repro-
ductive tissue, the data were analyzed with two-way 
ANOVA with Bonferroni multiple comparison using 




Study characteristics are presented in Table 1. There were 
no maternal cardiovascular diseases diagnosed besides 
preexisting hypertension or preeclampsia/HELLP. Severe 
FGR, defined as estimated fetal weight and/or abdominal 
circumference below the third percentile, was observed 
in ten out of 11 cases within the FGR group. One out of 
eight in the control group and four out of 11 in the FGR 
group were born prematurely. No neonatal death prior to 
discharged occurred. None of the neonates suffered from 
necrotizing enterocolitis or sepsis during neonatal inten-
sive care unit admission, interventricular hemorrhage 
occurred in two control patients, and idiopathic respira-
tory distress syndrome was diagnosed in one control and 
one FGR neonate.
Table 1 Maternal and neonatal characteristics
Data expressed as mean ± SD or n (%), respectively, tested with independent 
t test or Fisher’s exact test. # represents missing data, and therefore, 
the percentages are calculated based on the number of observations/
measurements within the control group with 7 being the lowest number of 
patients in a group (maximum 13% missing data). Pre-existing hypertension, 
preeclampsia and HELLP were defined according to the National Institute for 
Health and Care Excellence (NICE) guidelines [26]. GA: gestational age; HELLP: 
hemolysis, elevated liver enzymes and low platelet syndrome; and PPROM: 
preterm premature rupture of membranes
Control (n = 8) FGR (n = 11) p value
Maternal characteristics
Age (years) 29 ± 4 32 ± 5 0.11
(Pre-pregnancy) BMI (kg/m3) 25 ± 4 25 ± 4 0.96
Preexisting hypertension, 
n (%)
0 (0) 2 (18) 0.49
Renal disease, n (%) 0 (0) 1 (9) 1.00
Preexistent diabetes, n (%) 1 (13) 0 (0) 0.42
Autoimmune disease, n (%) 1 (13) 1 (9) 1.00
Preeclampsia, n (%) 0 (0) 5 (46) 0.05
HELLP, n (%) 0 (0) 1 (9) 1.00
PPROM, n (%) 3 (38) 0 (0) 0.06
Smoking, n (%) 2 (25) 5 (46) 0.63
Maternal medication during pregnancy
Antihypertensive drugs, n (%) 0 (0) 6 (55) 0.02
Antenatal steroids, n (%) 8 (100) 9 (82) 0.49
MgSO4, n (%) 3 (43)
# 4 (36) 1.00
Delivery
Caesarean section, n (%) 2 (25) 7 (64) 0.17
Apgar at 5 min 8 ± 2 8 ± 2 0.28
Neonatal characteristics
Sex, n (%male) 3 (38) 6 (55) 0.65
GA at birth (weeks) 31.1 ± 2.6 34.6 ± 3.5 0.02
Birth weight (gram) 1681 ± 416 1596 ± 459 0.69
Birth weight (percentile) 66 ± 20 6 ± 12  < 0.01
 - < 3rd percentile, n (%) 0 (0) 8 (73)  < 0.01
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Differential expression of genes
Multidimensional scaling (MDS) plots showed clustering 
in the study population (FGR vs. CON) as potential mod-
ifiers, but not in delivery route, prematurity or sex (Addi-
tional file 3: Figure S1). PCA plots also showed clustering 
between FGR vs. CON (Additional file 4: Figure S2). All 
of the study characteristics were tested for association 
for all the first ten PCs, and study population was asso-
ciated with PC1, PC3, PC4 and PC6; delivery route was 
associated with PC1 and PC7, and gestational stage with 
PC6 (Additional file  5: Table  S3). Therefore, differences 
in expression due to sex, mode of delivery, and gesta-
tional stage were accounted for in the modeling of gene 
expression.
Three protein-coding genes and one long intergenic 
noncoding (linc)RNA gene were significantly regulated 
(with a FDR < 0.1; Additional file  6: Table  S4) in FGR 
compared with control samples: 1) lectin, galactoside-
binding, soluble, 1 (LGALS1), 2) formyl peptide receptor 
3 (FPR3), 3) nurim nuclear envelope membrane protein 
(NRM), 4) lincRNA RP5-855F14.1; all protein-coding 
genes were downregulated and lincRNA gene was upreg-
ulated (Fig. 1).
Differential expression of gene sets
In total, 336 gene sets were significantly different 
between FGR and CON (with a FDR < 0.1; Additional 
file  7: Table  S5). Selection of only the highest ranking 
gene set module (overlapping modules excluded) resulted 
in 193 downregulated and 22 upregulated gene sets in 
FGR versus control samples. The downregulated gene 
sets are mostly involved with immune, inflammatory 
or cell cycle pathways. As we were interested in risk of 
developing cardiovascular or renal disease, we noticed 
that the several gene sets related to renal development 
were significantly upregulated and a few related to car-
diovascular health and function were downregulated 
in FGR samples vs. CON samples (Table  2). Heatmaps 
were made to study the extent of up and downregulation 
for the distinct genes in these gene sets in each sample 
(Additional file  8: Figure S3). From this analysis, most 
genes were up- and downregulated in accordance with 
the differential gene set analysis results.
DNA methylation
The percentage methylation was measured at each indi-
vidual CpG position for selected areas of the promoters 
of the three protein-encoding genes LGALS1, FPR3 and 
NRM per study population (Table  3). LGALS1 showed 
similar percentage of methylation at each individual CpG 
position between groups, independent of sex (Fig.  2). 
DNA hypomethylation differed between in FGR males 
versus CON males at CpG2 of FPR3 only (Additional 
file 9: Figure S4). NRM was significantly hypermethylated 
at CpG1 in FGR compared to control, especially in male 
FGR offspring (Fig. 3).
Discussion
This study examined developmental cardiovascular and 
renal programming profiles in HUVECs collected from 
pregnancies complicated by placental insufficiency-
induced FGR compared to normal growth pregnancies 
to identify targets underlying long-term cardiovascular 
and renal diseases. We report downregulated expression 
of the protein-coding genes LGALS1, FPR3 and NRM 
and upregulation of the lincRNA RP5-855F14.1 in FGR 
samples compared to controls. Sex-dependent DNA 
methylation might partially underlie FPR3 and NRM 
gene expression, but we did not observe this for LGALS1. 
Additionally, of the significantly differentially expressed 
gene sets, the downregulated ones were mostly involved 
with immune, inflammatory, or cell cycle pathways. 
Interestingly, seven of the 22 significantly upregulated 
gene sets related to kidney development and four gene 
sets related to cardiovascular function and health dif-
fered between FGR and control.
Downregulated expression of LGALS1
LGALS1 is the protein coding gene for galectin-1 (Gal-1) 
[27]. During pregnancy, Gal-1 is important for immu-
nomodulatory and vascular adaptions required for 
healthy placentation [28–30]. In HUVECs, Gal-1 medi-
ates angiogenesis via vascular endothelial growth factor 
receptor (VEGFR)-2 but also the neuropilin receptor 
(NPR)-1 which enhances the binding between VEGF and 
Fig. 1 Gene expression values of the genes that significantly differed 
between fetal growth restriction and control. TMM normalized gene 
expression of lectin galactoside-binding soluble 1 (LGALS1), formyl 
peptide receptor 3 (FPR3), nuclear envelope membrane protein (NRM) 
and RP5-855F14.1 in human umbilical vein endothelial cells collected 
from pregnancies complicated by fetal growth restriction (FGR) 
compared to control (CON). CPM, count per million. Data shown as 
mean ± SD
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VEGFR-2 [29, 31]. Freitag et al. also showed that LGALS1 
expression was downregulated in placentas derived from 
early-onset preeclamptic patients, which is a placental 
insufficiency syndrome just as in FGR and part of our 
study population [30]. In addition, in a mouse model 
inhibition of Gal-1 mediated angiogenesis resulted in 
preeclamptic symptoms and fetal growth restriction [30]. 
However, higher or no difference in Gal-1 expression was 
observed in term placentas from pregnancies compli-
cated by respectively preeclampsia or FGR [32, 33]. Con-
sidering the different histopathology between early-onset 
and late-onset FGR (or preeclampsia), the downregulated 
LGALS1 expression in early-onset FGR speculatively 
contributes directly to placental insufficiency, while the 
upregulated expression observed in late-onset FGR might 
be secondary to relative placental–umbilical hypoxia 
or reduced umbilical flow [30, 32, 34]. Gal-1 has been 
suggested as an early marker of endothelial dysfunction, 
and dysregulated Gal-1 has been linked to poor blood 
pressure regulation and development of cardiovascular 
disease [27, 28]. Therefore, the finding of downregulated 
LGALS1 expression in our FGR samples might be the 
key regulator leading to placental insufficiency-induced 
FGR, as well as an indication for the possible higher risk 
of developing long-term cardiovascular dysfunction in 
these offspring. Epigenetic processes or post-transcrip-
tional modifications other than DNA methylation might 
be involved in reduced LGALS1 expression.
Downregulated expression of FPR3 and NRM and 
upregulation of lincRNA RP5‑855F14.1
In contrast to LGALS1, FPR3, NRM, and RP5-855F14.1 
are less studied genes, especially in the context of FGR 
and pregnancy. To our knowledge, this is the first study 
Table 2 Significantly different gene sets related to renal and cardiovascular development, function or health
Ordered according to lowest false discovery rate (FDR)
Gene set name Up or down p value FDR Brief description
KEGG_CARDIAC_MUSCLE_CONTRACTION Down 0.0002 0.0052 Contraction of the heart is a complex process initiated by 
the electrical excitation of cardiac myocytes
GO_KIDNEY_EPITHELIUM_DEVELOPMENT Up 0.0003 0.0080 The process whose specific outcome is the progression of 
an epithelium in the kidney over time, from its formation 
to the mature structure
GO_RENAL_FILTRATION Up 0.0003 0.0081 Renal system process in which fluid circulating through 
the body is filtered through a barrier system
GO_RENAL_SYSTEM_VASCULATURE_DEVELOPMENT Up 0.0007 0.0126 The process whose specific outcome is the progression 
of vasculature of the renal system over time, from its 
formation to the mature structure
GO_CARDIAC_SEPTUM_DEVELOPMENT Up 0.0009 0.0145 The progression of a cardiac septum over time, from its 
initial formation to the mature structure
REACTOME_ERYTHROPOIETIN_ACTIVATES_PHOSPHO-
INOSITIDE_3_KINASE_PI3K
Down 0.0012 0.0172 Erythropoietin activates phosphoinositide-3-kinase
GO_RENAL_SYSTEM_DEVELOPMENT Up 0.0015 0.0207 The process whose specific outcome is the progression 
of the renal system over time, from its formation to the 
mature structure
REACTOME_SIGNALING_BY_ERYTHROPOIETIN Down 0.0026 0.0296 Signaling by erythropoietin
GO_KIDNEY_MESENCHYME_DEVELOPMENT Up 0.0042 0.0426 The biological process whose specific outcome is the 
progression of a kidney mesenchyme from an initial 
condition to its mature state. This process begins with 




Down 0.0067 0.060 Cell surface interactions at the vascular wall
REACTOME_SYNTHESIS_OF_VERY_LONG_CHAIN_FATTY_
ACYL_COAS
Down 0.0079 0.0671 Synthesis of very long-chain fatty acyl-CoAs
GO_CELL_DIFFERENTIATION_INVOLVED_IN_KIDNEY_
DEVELOPMENT
Up 0.0088 0.0712 The process in which relatively unspecialized cells acquire 
specialized structural and/or functional features that 
characterize the cells of the kidney as it progresses from 
its formation to the mature state
GO_REGULATION_OF_GLOMERULAR_FILTRATION Up 0.0115 0.0847 Any process that modulates the frequency, rate or extent 
of glomerular filtration. Glomerular filtration is the 
process in which blood is filtered by the glomerulus into 
the renal tubule
REACTOME_TRIGLYCERIDE_METABOLISM Down 0.0141 0.0947 Triglyceride metabolism
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reporting downregulated expression of FPR3 and NRM 
and upregulation of RP5-8551F14.1 in HUVECs or other 
pregnancy tissues collected from pregnancies compli-
cated by FGR. One study in mice suggested that NRM 
might be involved in early cardiac development [35]. 
While lincRNAs in general have been described to be 
epigenetic process-associated with cardiovascular dis-
ease and development, the exact function of this specific 
lincRNA is unknown [24, 36]. In humans, circulating 
FPR3 mRNA in combination with three other circulating 
mRNA had a high specificity and sensitivity to predict 
early-onset PE [37], but little is known on FPR3 expres-
sion or function. Recent studies did link downregulated 
expression of FPR2—another member of the FPR family 
with high analogies in sequencing identity and down-
stream responses [38]—in placental tissue to endothe-
lial dysfunction and placental insufficiency via impaired 
immunomodulatory and angiogenic processes, leading 
to FGR [39, 40]. FPR2 has also been described to play a 
protective and repairing role in ischemic heart disease 
and stroke [41, 42]. Considering the similarities between 
FPR2 and FPR3 [38], the observed downregulation of 
FPR3 in our placental insufficiency-induced HUVECs 
samples could potentially contribute to placental insuffi-
ciency in a similar manner and dysregulated FPR3 might 
contribute to the increased susceptibility to cardiovascu-
lar disease.
DNA methylation might partly contribute to the dif-
ferential gene expression patterns of FPR3 and NRM in a 
sex-dependent manner. The sex dependency is especially 
interesting given that hypertension is more pronounced 
in fetal growth restricted male offspring [6, 8, 43]. How-
ever, while the methylation differences are significant for 
NRM, they are relatively small suggesting that the regu-
lating role of DNA methylation in NRM expression is not 
strong. In addition, FPR3 is expressed, while the CpGs 
show hypermethylation; since the closest CpG position 
is almost 400  bp upstream of the TSS (although not by 
exclusion), its methylation possibly has little regulatory 
effects.
Cardiovascular and renal gene sets
We focused our gene set analysis on cardiovascular and 
renal development and function, since FGR has been 
associated with increased susceptibility to develop car-
diovascular and renal disease. The four different cardio-
vascular gene sets, including lipid metabolism, might be 
in line with the cardiovascular risk profile described with 
dysregulated expression of LGALS1 and RP5-8551F14.1. 
While the gene sets related to cardiovascular develop-
ment were similar in both groups, several gene sets 
related to kidney development were relatively upregu-
lated in FGR. Nephrogenesis starts around 22  days 
of gestation and is complete at 34–36  weeks of gesta-
tion, making pregnancy the most vulnerable period to 
impact nephron endowment [44]. FGR has been linked 
to reduced nephron count and morphological differences 
in glomeruli, which could lead to glomerular hyperten-
sion and compensatory hyperfiltration in the remaining 
nephrons, causing subsequent nephron loss (Brenner 
hypothesis) [45]. A recent study using three different rat 
models for FGR also reported that molecular pathways 
differed in kidneys from FGR and control male offspring 
at birth and at postnatal day seven (end of nephrogen-
esis in rats) [46]. The pathways involved depended on 
the stage of development, and most upregulation was 
observed in the placental insufficiency-induced model 
(best matching our study population). The upregula-
tion of the gene sets related to kidney development in 
our study, although not evident at individual gene level, 
suggests that developmental programming difference as 
a consequence of FGR is a subtle process. In an animal 
study, upregulation of renal genes in combination with 
wider nephrogenic zones suggested delayed nephro-
genesis in FGR [47]; however, due to ethical reasons, we 
cannot confirm this histologically. Therefore, whether 
the upregulation in HUVECs represents accelerated or 
delayed kidney development and whether this relates 
to long-term renal function or disease remain to be 
elucidated.
Strengths and limitations
This is the first study using HUVECs to investigate devel-
opmental programming differences between placental 
Table 3 DNA methylation of  each CpG position 
for  the  three highest significantly different expressed 
genes
Data expressed as mean ± SD tested with independent t test or median (min–
max) tested with Mann–Whitney. †7 instead of eight samples
Gene CpG position Methylation (%)
Control (n = 8)
Methylation (%)
FGR (n = 11)
p value
LGALS1 CpG1 15.88 ± 8.87 13.61 ± 9.44 0.60






CpG4 8.63 ± 4.71† 8.05 ± 5.32 0.82
FPR3 CpG1 93.55 ± 1.21 92.60 ± 1.24 0.11
CpG2 96.15 ± 1.31 94.68 ± 2.14 0.10
NRM CpG1 0.98 ± 0.31 1.72 ± 0.47 0.001
CpG2 2.20 ± 0.53 2.21 ± 0.63 0.96
CpG3 6.97 (2.21–10.71) 6.78 (6.03–10.30) 0.72
CpG4 5.09 (3.67–10.31) 5.76 (4.39–8.63) 0.31
CpG5 3.01 ± 0.88 2.89 ± 0.84 0.77
CpG6 2.68 ± 0.89 3.09 ± 1.05 0.38
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insufficiency-induced FGR and controls by a full-tran-
scriptome RNA-sequencing approach followed by dif-
ferential gene and gene set expression analysis and 
follow-up DNA methylation assaying. The gene set analy-
sis focused on cardiovascular and renal development, to 
specifically test the hypothesis that this correlate with 
increased risk for diseases of these systems can already 
be found during pregnancy. The transcriptomic profil-
ing by RNA-sequencing enabled us to find FGR associ-
ated gene expression differences in an unsupervised 
manner, and to select genes for the analysis of DNA 
methylation. A major strength is that we used prenatal 
ultrasound measurements to clearly define the placental 
insufficiency-induced FGR phenotype in our study popu-
lation; most studies use birth weight as surrogate marker, 
but this umbrella term also includes other underlying 
mechanisms such as congenital disorders or constitu-
tionally small children, which have not been exposed to 
a hostile in utero environment. The strength of investi-
gating HUVECs is that they allow us to investigate fetal 
expression differences without the interference of mater-
nal cells. Additional strengths are that we did not culture 
Fig. 2 DNA methylation at individual CpG positions for LGALS1. a The examined CpG positions in relation to the transcription start site (TSS); b DNA 
methylation at CpG1; c DNA methylation at CpG2; d DNA methylation at CpG3; e DNA methylation at CpG4 in fetal growth restriction (FGR) (n = 11) 
vs. control (n = 8). Data shown as Mean ± SD. Tested with two-way ANOVA with Bonferroni multiple comparison. LGALS1, lectin galactoside-binding 
soluble 1
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Fig. 3 DNA methylation at individual CpG positions for NRM. a The examined CpG positions in relation to the transcription start site (TSS); b DNA 
methylation at CpG1; c DNA methylation at CpG2; d DNA methylation at CpG3; e DNA methylation at CpG4; f DNA methylation at CpG5; g DNA 
methylation at CpG6 in fetal growth restriction (FGR) (n = 11) vs. control (n = 8). Data shown as mean ± SD. Tested with two-way ANOVA with 
Bonferroni multiple comparison. NRM, nurim nuclear envelope membrane protein
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our collected HUVECs and that we isolated the HUVECs 
within 24 h after delivery which limits external influences 
on epigenetic results.
While our strictly defined study population created a 
clear placental insufficiency-induced FGR phenotype, it 
also limited the number of included samples. However, 
(post hoc) power calculations for RNA-seq data are not 
well developed and as such not custom to use for this type 
of analysis. Instead, we relied on multiple testing corrects, 
and variation estimates build into the edgeR pipeline to 
properly analyze our data. Although beyond the scope of 
our study, we acknowledge that we cannot correlate gene 
expression findings to long-term outcomes. Gestational 
age at birth differed between groups, but we accounted 
for this factor in modeling gene expression and plots of 
gene expression per sample versus gestational age at 
birth showed that this was not of influence. The down-
side of not culturing our HUVECs was that the yielded 
RNA concentrations were relatively low. However, care-
ful consideration of the number of reads and nonzero 
genes in all samples allowed detection and exclusion of 
low-quality samples. Despite extensive washing, HUVEC 
samples might have been contaminated with a few other 
fetal blood cells. Other (epi)genetic mechanisms besides 
DNA methylation possibly involved in differentially regu-
lated expression of genes were not tested. Confirmation 
of our programming hypothesis includes verification in 
other tissues.
Summary and future perspectives
In conclusion, this study showed downregulated 
expression of LGALS1, FPR3 and NRM and upregula-
tion of RP5-855F14.1 in HUVECs collected from pla-
cental insufficiency-induced FGR compared to control. 
Additionally, several gene sets related to kidney devel-
opment were upregulated and a few gene sets related to 
cardiovascular risk were downregulated in FGR. How 
these findings correlate with long-term cardiovascular 
and renal function requires further investigation and 
follow-up studies. The differentially expressed genes (or 
their encoded protein) might be used as a biomarker, 
which could contribute to personalized care by pre-
dicting the risk of developing cardiorenal disease and 
selective follow-up of only the patients at risk. Further 
studies are also required to elucidate how and whether 
the downregulation of LGALS1 and FPR3 are causal 
regulators resulting in placental insufficiency-induced 
early-onset FGR as they might hold promise as poten-
tial novel targets for preventive treatment. While the 
findings of this study are the first to support the concept 
of developmental epigenetic programming of cardiore-
nal disease following placental insufficiency-induced 
FGR in humans, they are also merely the first of many 
steps toward clinical applicability.
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